Results 71 to 80 of about 50,615 (267)

Macrophage TNF-α mediates parathion-induced airway hyperreactivity in guinea pigs. [PDF]

open access: yes, 2013
Organophosphorus pesticides (OPs) are implicated in human asthma. We previously demonstrated that, at concentrations that do not inhibit acetylcholinesterase activity, the OP parathion causes airway hyperreactivity in guinea pigs as a result of ...
Allison D. Fryer   +12 more
core   +1 more source

A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials

open access: yesEpilepsia, EarlyView.
Abstract Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.
Elisa R. Zanier   +82 more
wiley   +1 more source

Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands [PDF]

open access: yes, 2019
In this study, we report a ligand-guided homology modeling approach allowing the analysis of relevant binding site residue conformations and the identification of two novel histamine H3 receptor ligands with binding affinity in the nanomolar range.
Hagenow, Stefanie   +3 more
core   +2 more sources

Status epilepticus: Updates on mechanisms and treatments

open access: yesEpilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

open access: yesJournal of Experimental Pharmacology, 2020
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, San Filippo Neri Hospital, Rome, Italy; 3Department of ...
Ora J   +4 more
doaj  

Beneficial effects of anisodamine in shock involved nicotinic anti-inflammatory pathway

open access: yesFrontiers in Pharmacology, 2011
Anisodamine, an antagonist of muscarinic receptor, has been used therapeutically to improve blood flow in circulatory disorders such as septic shock in China since 1965.
Ting eZhao   +4 more
doaj   +1 more source

A molecular basis for selective antagonist destabilization of dopamine D3 receptor quaternary organization [PDF]

open access: yes, 2017
The dopamine D3 receptor (D3R) is a molecular target for both first-generation and several recently-developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial Intensity Distribution Analysis indicated that a ...
Caltabiano, Gianluigi   +6 more
core   +2 more sources

The effects of royal jelly on human health: A narrative review of clinical studies

open access: yesJSFA reports, EarlyView.
Abstract Royal jelly (RJ) is a natural bioactive substance with documented effects on human health. This narrative review synthesizes evidence from clinical and clinically relevant experimental studies evaluating the therapeutic potential of RJ.
Goras Georgios   +2 more
wiley   +1 more source

Data regarding M1 muscarinic receptor-mediated modulation of hepatic catalase activity in response to oxidative stress

open access: yesData in Brief, 2016
We recently demonstrated the role of M1 muscarinic receptors (M1R) in modulating oxidative stress in liver and hepatocytes (Urrunaga et al., 2015) [1]. Here we provide data regarding the effect of a novel M1R agonist, VU0357017 (Lebois et al., 2010) [2],
Ravirajsinh N. Jadeja   +3 more
doaj   +1 more source

The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease [PDF]

open access: yes, 2014
Background: Olodaterol is a once-daily long-acting β2-agonist being investigated for the treatment of chronic obstructive pulmonary disease, with ≥ 24 hour bronchodilator activity.
Aumann, Joseph-Leon   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy